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S U M M A R Y
The duration of a protective level of yellow fever antibodies after autologous hematopoietic stem cell
transplantation in a previously vaccinated person is unclear. The case of a patient who had previously
been vaccinated for yellow fever and who remained seropositive for 22 months after autologous
peripheral blood stem cell transplantation for malignant lymphoma is described herein.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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Yellow fever is endemic in tropical regions of Sub-Saharan
Africa and South America and there are an estimated 200 000 cases
of yellow fever and 30 000 resulting deaths worldwide each year.1
Vaccination is strongly recommended for travelers who visit areas
endemic for yellow fever in Africa and South America and is also
required by International Health Regulations to enter some
countries.1 As the yellow fever vaccine contains live virus, it is
generally recommended that it should not be administered to
immunocompromised persons, including hematopoietic stem cell
transplantation (HSCT) recipients.2 However, the degree and
duration of immunosuppression are highly variable depending
on the type of transplant (allogeneic or autologous), type of donor,
and stem cell source. Although there have been sporadic reports
of successful immunization against yellow fever among post HSCT
patients,2 the information on yellow fever immunization among
HSCT recipients is still limited. In addition, to the best of our
knowledge, there has been no information regarding seropositivity* Corresponding author. Tel.: 3-3202-7181; fax: 3-3207-1038.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).for yellow fever in a previously vaccinated autologous HSCT
recipient. The case of a patient who had been vaccinated previously
for yellow fever and who remained seropositive for 22 months
after autologous HSCT for malignant lymphoma is described below.
2. Case report
A 58-year-old male was diagnosed with malignant lymphoma
in February 2012 and was treated initially with seven courses of
chemotherapy (six courses of R-CHOP (rituximab, cyclophospha-
mide, doxorubicin, vincristine, and prednisolone) and one course
of R-CHASE (rituximab, cyclophosphamide, cytarabine, etoposide,
and dexamethasone)). Following complete remission, he underwent
an autologous peripheral blood stem cell transplantation (PBSCT)
in August 2012. His clinical course after the transplant was stable,
without any relapse of lymphoma or infectious complications.
He worked for a trading company and often traveled to
countries outside of Japan, including South America. Prior to
treatment of the malignant lymphoma, he had been administered
the yellow fever vaccination twice, approximately 10 years and
20 years previously. Twenty-two months after the completion of
treatment for the malignant lymphoma, he consulted our travel
clinic in June 2014 as he required an additional yellow feverciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
K. Hayakawa et al. / International Journal of Infectious Diseases 37 (2015) 9–1010vaccination. Physical examination ﬁndings and blood tests were
normal, and he had a normal complete blood count. His serum
yellow fever IgG titer was measured using an ELISA, the result of
which was positive (2.1; negative titer 1.9). In addition, his serum
yellow fever antibody neutralizing titer was 1:20 (seroprotective
titer 1:10). Thus, it was concluded that an additional vaccination
was unnecessary. He was also conﬁrmed, after 17 months of auto-
HSCT, to be seropositive for measles IgG (33.1; negative titer <2.0),
rubella IgG (26.8; negative titer <2.0), varicella IgG (61.0; negative
titer <2.0), and mumps IgG (3.9; negative titer <2.0), for which he
did not have documentation of vaccination; furthermore, it was
unclear whether he had been vaccinated or had had the diseases
in childhood.
3. Discussion
To the best of our knowledge, this is the ﬁrst report to describe
persistent seropositivity for yellow fever in a previously vaccinated
autologous HSCT recipient. Previous reports have suggested that
neutralizing antibodies can be persistently protective for a long
period of time in an immunocompetent patient,3 and the World
Health Organization Strategic Advisory Group of Experts has
recently concluded that a single dose of yellow fever vaccine is
sufﬁcient to confer sustained immunity and lifelong protection
against yellow fever disease and that a booster dose of the vaccine
is not needed.1 However, the duration of a protective level of
yellow fever antibodies after autologous HSCT in a previously
vaccinated person is unclear.
Previous reports regarding the immunological status of other
viral diseases for which live vaccines are available have suggested
that patients with previous disease retain higher seropositivity
than patients who have been immunized. For example, Ljungman
et al. reported probabilities of 60%, 73%, and 52% for seronegativity
for measles, mumps, and rubella, respectively, at 5 years after
allogeneic HSCT.4 In contrast, Pauksen et al. reported that 12%, 18%,
and 6% of patients who were seropositive for measles, rubella, and
mumps, respectively, before autologous bone marrow transplan-
tation (BMT) became seronegative 1 year after BMT.5 These
differences suggest that persistent immunity after HSCT is
different between allogeneic and autologous HSCT, probably due
to the fact that autologous HSCT is generally less immunosuppres-
sive than allogeneic HSCT. Therefore, patients who undergo
autologous HSCT might have a higher chance of seropositivity
against vaccine-preventable diseases for which they have been
immunized previously.
The current Infectious Diseases Society of America guideline on
vaccination of the immunocompromised host recommends that
both allogeneic and autologous HSCT recipients avoid the yellow
fever vaccine.2 In contrast, a few reports have described the safe
administration of yellow fever vaccine to post allogeneic HSCTpatients.2 The European Group for Blood and Marrow Transplan-
tation guidelines on the vaccination of stem cell transplant
recipients recommend that yellow fever vaccination for travelers
should be determined based on individual assessment.4 Collec-
tively, this information suggests that yellow fever vaccination in
autologous HSCT patients might be possible under certain
conditions. Furthermore, the current case report suggests that it
is possible for a previously vaccinated autologous HSCT recipient to
maintain positive yellow fever antibody after HSCT; thus,
measuring the titer would provide valuable information for the
necessity of revaccination in this population.
Our patient received two doses of yellow fever vaccine prior to
autologous HSCT, which may have contributed to his seropositivity
after HSCT. Further studies are warranted to determine whether
a single dose of yellow fever vaccine is enough to maintain a
seroprotective status after allogeneic HSCT. In addition, because
the patient’s yellow fever antibody titer was measured 22 months
after autologous HSCT, it is possible that the titer will decline in the
future.
With developments in advanced medical treatments, an
increasing number of patients with hematologic malignancies
will experience a recovery sufﬁcient to allow travel abroad. The
immunocompromised status of these patients could vary widely,
and individualized assessment of the risks and beneﬁts of travel-
related vaccination is imperative.
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